INVESTOR RELATIONS
press release – price-sensitive
05/11/2026
REVENUE AS OF 30 SEPTEMBER 2026 AMOUNTING TO APPROXIMATELY 4.0 MILLION EUROS, AN INCREASE OF 12.7% COMPARED TO THE SAME PERIOD IN 202529/09/2026
THE BOARD OF DIRECTORS HAS APPROVED THE HALF-YEARLY REPORT AS OF 30 JUNE 202622/09/2026
FINANCING AND THE AWARD OF FUNDING FOR THE NEX-BIO PROJECT, WORTH 2 MILLION EUROS14/07/2026
REVENUE AS OF JUNE 30, 2026, AMOUNTING TO APPROXIMATELY 3.0 MILLION EUROS, AN INCREASE OF APPROXIMATELY 17.7% COMPARED TO THE SAME PERIOD IN 202506/05/2026
TURNOVER AS OF MARCH 31, 2026 EQUAL TO APPROXIMATELY 1.6 MILLION EUROS21/04/2026
FINANCING AND GRANTING OF FUNDING FOR THE ‘RE-FOOD’ PROJECT IN THE AMOUNT OF €720,00009/04/2026
PUBLICATION OF NOTICE OF CALL FOR ORDINARY SHAREHOLDERS’ MEETING27/03/2026
THE BOARD OF DIRECTORS HAS APPROVED THE DRAFT FINANCIAL STATEMENTS AS OF 31 DECEMBER 202510/02/2026
TURNOVER AS OF 31 DECEMBER 2025 AMOUNTING TO €4.6 MILLION, AN INCREASE OF 11.42% COMPARED TO THE SAME PERIOD IN 2024

ATTENZIONE: